The BRIF: Success Factors and Crucial Considerations for Ensuring Impact. by Lisa  B. Miranda
The BRIF: Success Factors and Crucial 
Considerations for Ensuring Impact
Lisa B Miranda
President/CEO, Biobusiness Consulting Inc
BRIF Workshop: 18 January 2011
Novotel Campans Cafferelli
Toulouse, France
N
a
t
u
r
e
 
P
r
e
c
e
d
i
n
g
s
 
:
 
d
o
i
:
1
0
.
1
0
3
8
/
n
p
r
e
.
2
0
1
1
.
5
8
7
7
.
1
 
:
 
P
o
s
t
e
d
 
4
 
A
p
r
 
2
0
1
1
Predicting Success Factors -2010
In May 2010, I was asked to submit my thoughts 
for a column for the Journal of 
Biopreservation and Biobanking
Question: “What do you see as the biggest 
challenges and opportunities for 
Biorepositories in the next 3 - 5 years?”
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“For Biobanks, in the near and long term the 
biggest challenges and opportunities are in 
many ways one and the same.  Both involve 
the field’s ability not only to continue to 
dramatically advance, but to harness its full 
potential via innovation to ensure 
actualization of impact.”
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“The ability for Biobanks to embrace the 
changing perspective of viewing the 
biospecimen as a potential work product 
and provide focus on the life cycle and 
related process chain and related pipeline 
planning will be hugely beneficial.”
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“Towards this pathway a few key things will be 
incredibly important in fostering success: 
voluntary adaptation related to necessary 
cultural changes to further cement and centralize 
appropriate infrastructure either in instituting 
center of excellence/biological resource center, 
core facility and/or integrated Biobank network 
models (in conjunction with tools to aide inter-
operability, formal induction and evolution 
towards best in tandem with integration of 
evidence based practice preparation) and 
Biobusiness activities (i.e. cost recovery 
implementation and fit for purpose resource 
organization and resource evaluation).”
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“Post implementation, these key steps will then contribute 
to foster viability as well as long term sustainability while 
providing equitable return on investment. 
The collaborative theory will then be put to the test as 
Biobanks transition from their current pre-competitive to the 
future competitive yet potentially collaborative environment. 
It will therefore be essential to demonstrate the “value 
add” of utilizing network tools, strategic alliances and 
private-public partnerships through proof of concepts pilots 
that offer shared equity and methodologies to categorize and 
aggregate sample collections, enhance overall quality of 
biospecimens and associated data and expedite collaboration 
aimed at discoveries which will ensure real time practice of 
molecular and personalized medicine such as those related to 
biomarker validation.”
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“It will also be crucially important to disseminate 
experiential lessons learned and scientific data 
amongst scientific and professional trans-boundary 
disciplines to create a fully operational evidence based 
environment.  This ability to achieve a trans-boundary 
educational, yet functional environment will succeed in 
reducing lags, roadblocks and related impediments that 
currently exist and may naturally occur along this 
pathway. In accordance with evolving biospecimen 
science, an additional challenge will be quantifying 
current “catch phrases” i.e. specimen integrity and 
benchmark specimens and quality marker reference 
ranges. Ideally these should then all be implemented back 
into the process chain and biospecimen lifecycle 
management process...  
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All the while, this management process 
should be protected by solid vocal public and 
private stakeholder support secured by 
prospective integration of appropriate policy 
and governance structures, which I believe 
will be the biggest challenge and opportunity 
of all.”
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Talk Overview
• Initial Areas of Impact
• Potential Applications
• Key Points of Integration
• Key Attributes and Success Factors
• Crucial Considerations for Design, Implementation & 
Evaluation
• Example of One Approach to Sample Indices 
• BREF Overview
• Recommendations for BRIF 
9Biobusiness Consulting Inc
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Bioresource Areas of Impact 
include but are not limited to:
Biospecimens, Expertise and Related Data all contribute to:
• Improvements in Clinical Care: from Prevention to Cure, QOL
• Advancements in 
– Clinical, Community & Biomedical Research
– Drug Discovery & Development
– Laboratory and Life Science
• Development of Medical, Scientific & Technological Innovations
– Instrumentation & Infrastructure
– Biospecimen Science & EBBP
– Biotechniques
• Education & Training
• Bioeconomic Health and Financial Growth of Organizations
10Biobusiness Consulting Inc
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BRIF: Potential Applications 
Primary Benefits Include Capability to:
• Stratify/Triage Bioresource via quality designation
– Facilitate educated decisions about which resources to fund, collaborate with, invest, 
partner…
– Assist Objectivity in Biospecimen Prioritization,  Utilization and Aggregation
• What do we really need to collect
• What collections are “utilization worthy”
• Which collections are most relative to aggregate with, match sample sets ( quality “apples to 
apples”)
• Annotate Progress – Future Outcomes
• Ensure/Protect/Document Return on Investment by tracking of related products, 
outcomes and impact.- bioresource and the field as a whole.
Secondary Benefits Include:
• Alleviate biobanking and related research outcome quality disparities
• Address Economic Issues- Justify real costs of biocollections to create economies of 
scale
11Biobusiness Consulting Inc
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Key Points of Integration
• Protocols, Study and Project design
– Quality driven (BRIF focused) protocols
– Methodology and Reporting Standards
• Bioresource Annual Evaluation
– End User Utilization Survey
– Stakeholder reports
– ROI indicator
• Bioresource Planning
– Biospecimen Prioritization  and Statistical Design Tool
– Grants/revenue and business planning
– R&D planning opportunities
– Organizational Road mapping
12Biobusiness Consulting Inc
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Key Attributes & Success Factors
• Relevance- degree and length
• Measurability & Reproducibility
• Statistical Significance & Validity
• Generalizeability & Interoperability
• Adoptability & Feasibility
• Sustainability & Adaptability
• Transformative power & Innovative ability
13Biobusiness Consulting Inc
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Crucial Considerations for BRIF: 
Design, Implementation and Evaluation (1)
• Quantitative and Qualitative?
– Would measurements have be subjective first than objective later, than refined over 
time a the BRIF evolves?  Do we measure + & - outcomes? 
• Range of Scope : Foci, Degree/Length of Effect/Outcome, End users, Discipline and 
Application
– Customized per discipline, inter-disciplinary BRIF points of interest
• Categories and Levels of Indices:  Band Width of Related CDE’s & Annotation
• Design Scale (Likert-like?), Weight, Scoring and Evaluatory Algorithms
• Considerations relevant to interpreting for Bias and Confounding Variability
• Targeted but Broad enough to glean relevance as to IMPACT
– Baseline standard that meets all Bioresources but does not limit initial level of quality 
measurement/practice
– One that will evolve as standards/practices/infrastructures evolve- BRIF-Bioresource 
POC (Proof of Concept) and then evolve
• BP, fit for purpose, EBBP, ….
14Biobusiness Consulting Inc
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Crucial Considerations for BRIF:
Design, Implementation & Evaluation (2)
• Time points for implementation and evaluation, 
evolution: Baseline, yearly; q2 years
• Method of Implementation- Manual,Automated?
• Logistics, procedures, policy and strategy as for:
– Integration into daily Bioresource operations
– Harmonization with adjunct workfows/processes
– Quality BRIF Reporting from Adjunct Bioresources
• Education and Training Requirements
• Methodology Related Documentation 
– - E.g. Do we link with reporting measures?
15Biobusiness Consulting Inc
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Breaking down the BRIF
• By Type of Bioresource By:
– Model
• Clinical, Disease, Population, Bench, Sample Management
– Population
• Human (Adult/Ped/Post mortem), Animal, Plant, Environmental
– Research and Clinical Foci (Diabetes, Cancer, HIV, Rare dz)
– Type of biospecimen(s); derivative(s);product(s)
• Blood/tissue/other; cDNA, RNA; TMA, assay, other…
– Level of Infrastructure
• Biobank, core bioresource, BRC, BRC/COE, Network
– Applicable Standards
• BP, level of GMP, regulations, policies
16Biobusiness Consulting Inc
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BRIF: Initial Categories of Evaluation
• Bioresource Specific Impact Factors could include:
• Quality Measurement/Scoring of:
– Samples/Collections/Data
– Analysis and Research Results
– Derivatives and Work Product
• Associated Tools, Technologies, Advancements
• Associated Outcomes: Clinical, Research, Other…
• Resulting Financial Health Indicators and BREF Data
Biobusiness Consulting Inc 17
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BRIF: Quality Factors
• Biospecimen Quality Scoring of 
– Direct measure per specimen, per collection
• Morphological, molecular analysis, quality correlates 
i.e. RIN to RIN
– MDS Data Annotation
– Quality of Work Product
• E.g. TMA, Blood
?- What are the quality factors?
Biobusiness Consulting Inc 18
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Initial Steps to Baseline BRIF
1. Define and List what BRIF related data points 
you want to measure, track and compare
2. Aggregate into relevant categories
3. Develop Standardized Minimal Data Sets and 
target quality reference ranges 
4. Score MDS
5. Weigh Scores
6. Total to find Baseline BRIF Score
Biobusiness Consulting Inc 19
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BRIF Outcome Index Example:
Biobanks
• Relevant BRIF Categories for Clinical Care 
Outcomes could include:
– Incidence and Prevalence of Disease
– Diagnostic and Treatment Outcomes
– Prevention and QOL Measures
– Others TBD
20Biobusiness Consulting Inc
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BRIF Clinical Outcome Sample Indices:
Clinical Diagnosis and Treatment (MDS)
• Decreased Lag to Diagnosis 
• Decreased Severity of Disease at Time of Diagnosis
• Decreased Time to Intervention and Initial Treatment
• Decreased Time to Surgery
• Increased Relevance of Correlated Clinical Pathology
• Increased Relevance of Related Research Finding
• Decreased Treatment Time
• Increased Efficacy of Pharmacological Intervention
• Decreased Incidence of Clinical Intervention related 
Complications, Serious Adverse Events
• Decreased lag to follow-up
21Biobusiness Consulting Inc
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BRIF Clinical Outcome Sample Indices:
Incidence and Prevalence of Disease (MDS)
• Increased Rate of Prevention 
• Increased Length of Survival with disease
• Increased Length of Survival post recovery
• Decreased 
• Prevalence rate overall
• Incidence rate overall
• Incidence of transmission
• Incidence of recurrence rates 
• Incidence of metastasis
• Death rate second to disease of relevance
22Biobusiness Consulting Inc
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BREF Overview
• BREF=Bioresource Research Economic Factors 
• BREF Historical
– Originally developed by L. Miranda as baseline Annual Reporting Criteria 
in 2005
– Presented to NIH 2006, then adopted and implemented into initial NIH 
BP guidance in 2007 (BP forums)-2009/10 (BP documents)
– Impetus, Intended Purpose and Application
• Quantitative Evaluation of Three Critical Questions:
– How Effectively Has The Bioresource Performed?
– What Impact Has the Bioresource Had On Research?
– Is There A Continuing Need For The Bioresource?
• Relevance to BRIF
– Template - can extrapolate and translate outcomes to be BRIF centric
23Biobusiness Consulting Inc
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BREF:
Quantifying Financial Performance
Financial Performance Impact Measures Include:
• $$ worth of specimens the resource has provided to researchers
• $$$ value of projects & researchers supported with 
specimens/services from the Bioresource
• $$$ value of different specimen types that the Bioresource has 
provided 
• $$$ value of difficult to obtain specimens made available to 
researchers by the resource 
• Funds recouped from Collections/Distributions/Bioresource 
Services, repeat requests 
• Grant Funding, Revenues and New projects funded from 
Bioresource related publications  and support 
• Cost efficiency reporting ($$$ Saved to Users) from innovation 
and/or tools, adherence to BP
• Per Specimen Savings
24Biobusiness Consulting Inc
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BREF:
Quantifying Financial Impact
Financial Impact Measures Include:
• Financial value of Bioresource’s contribution towards: 
– Published studies using resource specimens
– Registered Patents
– FDA approval of a medical device 
– Development of useful technologies 
• (LIMS/BIMS, instrumentation, robotics, consumables, telecommunications, 
equipment...)
– Development of useful research techniques 
– Development of infrastructure innovations (EBD)
– Financial Efficiency related feedback from users
– Determination of Cost per critical research finding
– Impact of the Bioresource on their research
– Financial impact of Institution from resource-related papers 
25Biobusiness Consulting Inc
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BREF:
Demonstrating Continuing Need
Key Continuing Need Evaluation Questions include: 
• Is the resource meeting its financial objectives? 
• Is the Use Cost Effective? 
• Is the Resource Financially Viable OR promoting sustainable development?
• Is the Value of specimens (and data) being provided (collected) worth the 
cost of running the Facility?
• What level of facilitation of scientific progress is necessary to support cost 
of operations? 
• Has the resource improved financial issues regarding access to specimens 
for PI’s?
• Evaluation of Financial issues related to duplication of effort 
• Are PI based banks competing with OR impeding funding for central 
biospecimen resource?
• Is the Bioresource still needed? 
• Financial comparison of alternative specimen sources  
• Does the resource still require Stakeholder/Adjunct funding or is it self-
sustaining?
26Biobusiness Consulting Inc
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Initial Recommendations (1)
1.  Utilize the BRIF to assist Bioresource 
capability:
– Create  Universal Quality Score to Increase
• Compatibility and relevance of collaboration, research 
specifically and overall
– Specimen A Quality = Specimen E Quality
– RIN to RIN
– Data set A commensurate with Data Set E
• Level of Adherence to Reporting Standards
– BRISQ to BRISQ, STARD TO STARD…..
Biobusiness Consulting Inc 27
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Initial Recommendations (2)
2.  Develop Minimal BRIF Data Set- “Mini-BRIF”
–Quality Indicators
–Outcome (in progress, short, long term)
• Track Work Products in all forms
• Direct Product, Related Research and Clinical 
Outcomes
–Economic Indicators
–Other TBD…
Biobusiness Consulting Inc 28
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Initial Recommendations (3)
3. Initially use as a manual Bioresource Tool to 
assist your current collaborations and Bioresource 
Development- Academic or otherwise…
4. Meanwhile Marry with Informatics Technology 
Application i.e. ORCID, others TBD
5. Pilot BRIF Tool across INSERM and BBMRI
6. Demonstrate “Proof of Concept”
– Manual v. Automated 
7. Publish as ROI Study and Technology Evaluation
8. Add BRIF tool into R&D BBMRI Tech Pipeline
Biobusiness Consulting Inc 29
N
a
t
u
r
e
 
P
r
e
c
e
d
i
n
g
s
 
:
 
d
o
i
:
1
0
.
1
0
3
8
/
n
p
r
e
.
2
0
1
1
.
5
8
7
7
.
1
 
:
 
P
o
s
t
e
d
 
4
 
A
p
r
 
2
0
1
1
Contact Information
Biobusiness Consulting Inc’s chief mission includes 
provision of innovative guidance aimed at reduction of 
biobanking quality related “disparities” performed in 
tandem with promotion of sustainable, equitable 
financial and business development to foster real time 
implementation of Best and Evidence based Biobanking 
practices in synergy with actuation of biospecimen 
research based strategic partnerships.
Contact: 001 978 323 9834 or 
lisa.miranda.007@gmail.com
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Merci
• BRIF Workshop Meeting Organizers
– Anne Cambon-Thomsen, Laurence Mabile, 
Gabrielle Bertier et al…
– INSERM
– Gen2Phen 
– BBMRI
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